Arkema Shares Gain 1% at Close, Driven by a Technical Rebound
Arkema's stock ended Wednesday up 1.08% at 51.25 euros. This increase follows a 5.76% rise over the last seven days, even as the specialty chemicals group remains hampered by a 34% decline over twelve months.
Arkema's stock price is now at 51.25 euros, above its previous closing level of 50.70 euros. Over the week, the stock has increased by nearly 6%, a movement reflecting a renewed interest after a marked downward trend over three months, with a decline of 2.57%. The 14-period RSI stands at 44, indicating a neutral market without overbuying or overselling. The 20-day moving average is at 51.80 euros, slightly above the current price, signaling proximity to a short-term technical resistance zone. The one-month volatility is at 10.39, indicating a moderate amplitude of recent fluctuations. These elements confirm a market stabilizing after the past year's turbulence.
Analyst Opinions Remain Mixed
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Analyst opinions on Arkema remain divided. UBS maintains a 'buy' recommendation, with a price target reduced from 64 to 61 euros on January 14, implying an upside potential of nearly 19% compared to the current price. Conversely, Bernstein remains cautious: on January 20, the bank reiterated its underperformance advice and lowered its target from 49 to 47 euros, suggesting a downside risk of 8% from Wednesday's closing level. These differing assessments illustrate the difficulty in evaluating the chemist's prospects in a contrasting sectoral context. The annual performance of -34% continues to weigh on the overall assessment, but the recent rebound indicates that some investors consider the stock undervalued.
Après des mois de janvier et février relativement faibles, la performance du premier trimestre a finalement été légèrement supérieure aux attentes.
Les volumes du Groupe sont stables, et la demande dans les segments clés est en hausse.
Risks mentioned
Impact potentiel de la crise au Moyen-Orient sur la demande mondiale.
Inflation des coûts des intrants résultant de la crise au Moyen-Orient.
Opportunities identified
Développement dans des marchés clés attractifs tels que les batteries et l'impression 3D.
Poursuite des efforts pour gérer strictement les coûts fixes.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
